Choledochal cyst presenting as pancreatitis: timing the operation and defining the resection
A 6-year-old girl has had three episodes of severe epigastric pain over five months, each with vomiting. Today she is afebrile with scleral icterus. Amylase is 1240 U/L, lipase 980, total bilirubin 3.4 mg/dL (direct 2.6), ALT 210, and WBC 11.2. Ultrasound shows a 3.2 cm cystic dilatation of the extrahepatic bile duct, gallbladder sludge, and a mildly dilated pancreatic duct; the intrahepatic ducts are not dilated. MRCP confirms a long common channel with pancreaticobiliary maljunction and no intrahepatic dilatation. She is tolerating oral fluids and her pain is controlled with acetaminophen.
1. What is the diagnosis, how do you manage the current episode, and when do you operate? What would force you to intervene on the biliary tree urgently?
Read the worked answer
This is a Todani type I choledochal cyst with pancreaticobiliary maljunction, presenting with acute pancreatitis and cholestasis. The reflux of pancreatic juice into the biliary tree through the long common channel is the driver of both the pancreatitis and the long-term malignant risk.
The acute episode is managed medically: isotonic fluid resuscitation, analgesia, antiemetics, and early enteral feeding as tolerated once the pain settles. Prophylactic antibiotics are not indicated for uncomplicated pancreatitis and do not change the course. I would track bilirubin, temperature, and white count for evidence of cholangitis.
Cholangitis is the finding that changes the tempo: fever with worsening jaundice and right upper quadrant pain means infected, obstructed bile and needs urgent drainage - endoscopic biliary stenting if the anatomy allows, or percutaneous cholecystostomy as a temporizing measure - followed by definitive surgery during the same admission. In the absence of cholangitis, definitive excision should be delayed about four to six weeks until the pancreatitis resolves and the periductal inflammation subsides, because dissection in an acutely inflamed porta hepatis is where ductal injuries and later strictures come from. ERCP is reserved for cholangitis, a retained stone, or persistent obstruction.
2. Describe your definitive operation and the technical decisions that most influence long-term outcome.
Read the worked answer
Cholecystectomy with complete excision of the cyst from the level of the common hepatic duct down to the pancreaticobiliary junction, followed by a Roux-en-Y hepaticojejunostomy.
The decisions that determine outcome are these. First, completeness of excision: leaving the distal intrapancreatic portion or any residual cyst mucosa behind preserves the malignant risk that motivated the operation. Second, protection of the pancreatic duct at the junction - this is the most hazardous part of the dissection and the reason to operate on a cooled-down patient. Third, the anastomosis: the duct at the common hepatic duct is often narrow, so a wide, mucosa-to-mucosa, tension-free, single-layer anastomosis with absorbable suture in a retrocolic Roux limb of 40 to 45 cm is essential; calibrating the anastomosis to the child's duct rather than to the size of the cyst is a common error. Fourth, intraoperative cholangiography to define the common channel and confirm ductal anatomy before transection.
The laparoscopic approach is acceptable in experienced hands with comparable outcomes, but the technical principles do not change. I would not attempt a cyst-enterostomy of any kind.
3. The parents ask about cancer risk and about follow-up. What do you tell them, and how would a 5 mm cyst differ?
Read the worked answer
Excision reduces but does not abolish the risk of cholangiocarcinoma, which is why the operation is done in childhood and why surveillance continues for life. The elevated risk comes from pancreaticobiliary reflux, chronic inflammation, and any residual cyst or anastomotic mucosa. Risk is higher when excision is delayed into adulthood and when cyst mucosa is left behind. I would tell the family plainly that the operation removes the main risk factor but not all of it, that the child needs annual liver function tests and ultrasound, and that any new stricture, stone, or ductal dilatation later in life should be investigated for malignancy rather than assumed benign. Transition to an adult hepatobiliary service should be planned, not accidental.
A 5 mm cystic lesion would reframe the problem. A small, intraduodenal cystic dilatation is a Todani type III choledochocele, which behaves differently and is usually managed by endoscopic sphincterotomy or marsupialization rather than by excision and Roux-en-Y reconstruction; a small type I cyst still warrants excision because the malignant risk is driven by the maljunction, not by the size. The distinction is anatomic, not dimensional, and getting it wrong in either direction is the real error.